Successful past conferences and symposiums that have led to a mulittude of workgroups and other collabortive efforts
Drug Discovery in Academia
The New Paradigm for Drug Discovery
A symposium was held on October 18, 2011 at the Baltimore Convention Center that brought together the pharmaceutical industry and academic-based research institutions with the common goal of exploring how the two can best work together to enhance and facilitate the discovery of new drugs.
Brain Science Institute Annual Symposium
The BSi inaugural annual symposium was held on Friday, April 29th, 2011, 8:00am-5:15pm, Wood Basic Science Auditorium, East Baltimore Campus. Presentations are available for viewing.
The Friends of The Axon, the Schwann Cell & Jack Griffin Scientific Symposium
The Friends of the Axon, the Schwann Cell, and Jack Griffin Scientific Symposium brought together friends and colleagues for a series of lectures and discussions about Peripheral Nerve, and provide an opportunity to celebrate Jack's contributions to neurology and neuroscience, and Johns Hopkins. As Jack has often said, "I found my "Nervana" in my research, colleagues and clinical care." This symposium honored Jack's enormous impact from research to practice, professional education to program development. In addition to his contributions in the field of nerve disease, as Chair of the Department of Neurology Jack had a pivotal role in the development of neurologists and neuroscientists at Hopkins and nationally. In the past 5 years he has directed the Johns Hopkins Brain Science Institute, and the event allowed us to celebrate the accomplishments and the future of the BSi. Presentations are available for viewing.
The Science of the Arts
The Science of the Arts brought together researchers and artists in a series of informal conversations about aesthetics and beauty in music, architecture, art and dance.
Biotech 2008 Neuroscience Investors Conference: Investing in Brain Research
More than 20 world-renowned scientists and industry leaders presented the current state of neurobiology research and discussed challenges of speeding drug discovery for brain diseases. The audience included more than 200 research scientists, leaders in the pharmaceutical and biotechnology industries, business development executives, venture capitalists, investment bankers, and consulting and legal service providers.